Sol-gel silica controlled release thin films for the inhibition of methicillin-resistant Staphylococcus aureus

Biomaterials

Volumn 35, Issue 1, 2014, Pages 509-517

  Bhattacharyya, Sanjib ^a   Agrawal, Ashwin ^a   Knabe, Christine ^b   Ducheyne, Paul ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Antibiotics; Controlled release; Drug delivery; Implant; MRSA; Sol gel silica

Indexed keywords

CONTROLLED RELEASE; EXTRACELLULAR MATRICES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MRSA; QUORUM-SENSING MOLECULES; SOL-GEL SILICA; SURGICAL SITE INFECTIONS; THERAPEUTIC STRATEGY;

ANTIBIOTICS; BACTERIA; BIOCHEMISTRY; DRUG DELIVERY; ENZYME INHIBITION; EXPERIMENTS; IMPLANTS (SURGICAL); SILICA; SOL-GELS; THIN FILMS; TRANSPLANTATION (SURGICAL);

SOL-GEL PROCESS;

FARNESOL; NANOROD; NANOWIRE; SILICON DIOXIDE; VANCOMYCIN;

ADJUVANT THERAPY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY DEVICE; DRUG EFFICACY; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MOLECULAR STABILITY; NONHUMAN; PRIORITY JOURNAL; REDUCTION;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

ANTIBIOTICS; CONTROLLED RELEASE; DRUG DELIVERY; IMPLANT; MRSA; SOL-GEL SILICA;

ANTI-BACTERIAL AGENTS; FARNESOL; GELS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; SILICON DIOXIDE; VANCOMYCIN;

EID: 84887026220     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.09.073     Document Type: Article

References (24)

1. Casewell M.W., Hill R.L. The carrier state: methicillin-resistant Staphylococcus aureus. JAntimicrob Chemother 1986, 18(Suppl.A):1-12.
2. Lowy F.D. Staphylococcus aureus infections. NEngl J Med 1998, 339:520-532.
3. Gordon R.J., Lowy F.D. Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008, 46(Suppl.5):S350-S359.
4. Hawkey P.M. Molecular epidemiology of clinically significant antibiotic resistance genes. Br J Pharmacol 2008, 153:S406-S413.
5. Klein E., Smith D.L., Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 2007, 13:1840-1846. http://www.cdc.gov/EID/content.
6. Antibiotic prophylaxis for surgery. Treatment guidelines 2004, vol. 2:27-32. The Medical Letter.
7. Fasola E.L., Peterson L.R. Laboratory detection and evaluation of antibiotic-resistant Staphylococcus aureus nosocomial infections. Advances in pathology 1992, vol. 5:285-306. Mosby-Year Book, Chicago, IL.
8. Hiramatsu K. Vancomycin-resistant Staphyloccus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001, 1:147-155.
9. Tverdek F.P., Crank C.W., Segreti J. Antibiotic therapy of methicillin-resistant Staphylococcus aureus in critical care. Crit Care Clin 2008, 24:249-260.
10. Jabra-Rizk M.A., Meiller T.F., James C.E., Shirtliff M.E. Effect of farnesol on Staphylococcus aureus biofilm formation and antimicrobial susceptibility. Antimicrobial Agents Chemother 2006, 50:1463-1469.
11. Gomes F.I.A., Teixeira P., Azeredo J., Oliveira R. Effect of farnesol on planktonic and biofilm cells of Staphylococcus epidermidis. Curr Microbiol 2009, 59:118-122.
12. Gomes F., Leite B., Teixeira P., Cerca N., Azeredo J., Oliveira S. Farnesol as antibiotics adjuvant in Staphylococcus epidermidis control invitro. Am J Med Sci 2011, 341:191-195.
13. Kaneko M., Togash N., Hamashima H., Hirohara M., Inoue Y. Effect of farnesol on mevalonate pathway of Staphylococcus aureus. JAntibiot 2011, 64:547-549.
14. Radin S., El-Bassyouni G., Vresilovic E.J., Schepers E., Ducheyne P. Invivo tissue response to resorbable silica xerogels as controlled-release materials. Biomaterials 2005, 26:1043-1052.
15. Radin S., Ducheyne P. Nanostructural control of implantable xerogels for the controlled release of biomolecules. Learning from nature to design new implantable biomaterials 2004, 59-74. Kluwer Academic Publishers, Netherland. R. Reis (Ed.).
16. Qu H., Bhattacharyya S., Ducheyne P. Sol gel processed oxide controlled release systems - overview. Comprehensive biomaterials 2011, vol. 4:475-495. Elsevier, Oxford, England.
17. Nicoll S.B., Radin S., Santos E.M., Tuan R.S., Ducheyne P. Invitro release kinetics of biologically active transforming growth factor-β1 from novel porous glass carrier. Biomaterials 1997, 18:853-859.
18. Vallet-Regi M. Ordered mesoporous materials in the context of drug delivery systems and bone tissue engineering. Chem Eur J 2006, 12:5934-5943.
19. Santos E.M., Radin S., Ducheyne P. Sol gel derived carrier for the controlled release of proteins. Biomaterials 1999, 20:1695-1700.
20. Radin S., Ducheyne P., Kamplain T., Tan B.H. Silica sol gel for the controlled release of antibiotics. Synthesis, characterization, and in invitro release. JBiomed Mater Res 2001, 57:313-320.
21. Aughenbaugh W., Radin S., Ducheyne P. Silica sol gel for the controlled release of antibiotics. II. The effect of synthesis parameters on the invitro release kinetics of vancomycin. JBiomed Mater Res 2001, 57:321-326.
22. Radin S., Ducheyne P. Controlled release of vancomycin from thin sol-gel films on titanium alloy fracture plate material. Biomaterials 2007, 28:1721-1729.
23. Reynolds P.E. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis 1989, 8:943-950.
24. Schilling A., Neuner E., Rehm S.J. Vancomycin: a 50-something-year-old antibiotic we still don't understand. Cleve Clin J Med 2011, 78:465-471.